Shanna Johnson Diversity, Equity & Inclusion Council | American Lung Association
+ Pharmaceuticals
Patient Daily | Jul 8, 2025

American Lung Association launches COPD support campaign targeting rural communities

The American Lung Association has initiated a campaign aimed at supporting individuals living with chronic obstructive pulmonary disease (COPD) across the United States, particularly in rural areas. The initiative addresses the needs of approximately 16 million Americans affected by this progressive lung disease.

COPD is characterized by restricted airflow and breathing difficulties. While it remains incurable, treatments such as supplemental oxygen, inhalers, medication, and lifestyle adjustments can alleviate symptoms and enhance quality of life. However, individuals in rural regions face higher COPD rates compared to urban counterparts, leading to increased hospitalizations and mortality rates.

The Living Well with COPD campaign offers free personalized support, education, and resources for all stages of the disease. This initiative primarily targets families in rural communities who may lack access to hospitals and other essential resources.

“Living well with COPD requires an evolving treatment plan, regular visits with a healthcare provider, and lifestyle modifications that can help you breathe better,” stated Harold Wimmer, President and CEO of the American Lung Association. “Unfortunately, many individuals, especially those living in rural communities, lack the support and access to essential care and resources that could greatly enhance their daily lives. For these individuals and their families, the Lung Association can help.”

The association collaborates with rural partners and local healthcare providers to extend its reach effectively.

For further information or assistance regarding COPD management through this campaign, contact the Lung Association’s HelpLine at 1-800-LUNGUSA or visit Lung.org/copd.

Support for this educational campaign is provided by Sanofi and Regeneron, AstraZeneca, Genentech, and GlaxoSmithKline.

Organizations in this story